Some evidence suggests that CYP3A4 may be involved in the activation of procarcinogens into their carcinogenic forms, potentially influencing cancer risk. Genetic polymorphisms in the CYP3A4 gene can lead to variations in enzyme activity, which might affect an individual's susceptibility to certain cancers. More research is needed to fully elucidate these relationships and their clinical implications.
